Boston Scientific has had a tough time catching up to peers in the transcatheter aortic valve replacement (TAVR) market, but the company's latest news about the Lotus valve has been well received by investors.
Some of medtech’s largest companies are working for approval in the TMVR space, which could one day rival or surpass TAVR.
JenaValve has started an early feasibility study of the Pericardial TAVR technology for the minimally invasive treatment of patients with symptomatic, severe aortic stenosis, and symptomatic, severe aortic regurgitation.
United Therapeutics and Medtronic have received FDA approval for the SynchroMed II to deliver medication to treat pulmonary arterial hypertension.
Reva has received CE mark for the Motiv bioresorbable scaffold to be used for the treatment of below-the-knee peripheral artery disease.
Abbott acquired Tendyne back in 2015, a year where there was significant M&A activity in the transcatheter mitral valve replacement space.
CEO Mike Mahoney assured investors that Boston Scientific's seemingly aggressive M&A activity this year has all been part of a "very well-laid plan" and that the company still sees plenty of future tuck-in deals over the next 12 months.
The TAVR space is heavily dominated in the U.S. and Europe by Edwards Lifesciences and Medtronic, but Meril said there is enough room in the market for more players.
The Marlborough, MA-based company is set to swoop in and pick up Claret Medical, an embolic protection specialist, in a deal worth $270 million.
Abbott Laboratories reported a strong second quarter overall, but in medical devices, the company appears to be losing share in cardiac rhythm management and neuromodulation. Could Abbott's loss in these markets be Medtronic or Boston Scientific's gain?
The company asked the court to dismiss a negligence case involving St. Jude Medical's Riata ST lead, but a federal judge denied the motion, allowing the case to proceed.
Otsuka Holdings is set to acquire ReCor Medical for an undisclosed sum and follows Medtronic in a bid to get a renal denervation device on the market.
FDA gave ReCor Medical the green light to run a pivotal study of its ultrasound-based renal denervation system for the treatment of hypertension.